Clear Creek Bio, Inc.

Promedior, Inc.

Integra Lifesciences Corporation

David Paul Hesson

Ping Huang

Mo Jia

Xianjun You

Vikram S Kumar

Michael Scott Kramer

Siyi Jiang

Chaoyi Deng

Qingqing Lu

Mark L Lupher, Jr

Teresa K Surowy

Timothy J Pelura

Abdolsamad Tadayon

Jinsuo Yang

Shawn Li

Glen D Frazer

Lin Cui

The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.

Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2'-halo-1-1′-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.

Compositions and methods for inhibiting dihydroorotate dehydrogenase

The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2'-halo-1-1&#x2032;-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.

The application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient's risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and/or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131/H131 polymorphism of Fc&#x3b3;RIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.

Methods for treating fibrosis using CRP antagonists

In certain aspects, the present invention provides compositions and methods for treating mucositis.

Methods and compositions useful in the treatment of mucositis

Provided is, among other things, a method of treating in an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death, the method comprising: (a) injecting a physiologically acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has an therapeutically effective amount an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume.

Treatment of neurological disease

Growing community of inventors

Malvern, PA, United States of America

David Paul Hesson